Author: FibroBiologics, Inc.

Posted Date:

April 20, 2026

FibroBiologics Compliant with All Nasdaq Listing Requirements

FibroBiologics, Inc.

April 20, 2026
FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics, Inc.

April 2, 2026
FibroBiologics Announces Pricing of $3 Million Public Offering

FibroBiologics, Inc.

March 31, 2026
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

FibroBiologics, Inc.

March 31, 2026
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

FibroBiologics, Inc.

March 25, 2026
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

FibroBiologics, Inc.

March 12, 2026
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

FibroBiologics, Inc.

March 5, 2026
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

FibroBiologics, Inc.

March 2, 2026
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update

FibroBiologics, Inc.

February 24, 2026
FibroBiologics Granted Extension by Nasdaq to Regain Compliance

FibroBiologics, Inc.

February 23, 2026